TNFRSF18 and neoplasm: In a neoadjuvant setting, results from a phase Ib clinical trial demonstrated that the GITR antibody MEDI6469 induced T cell proliferation and activity in the tumor microenvironment in 17 treatment-naïve patients with resectable HNSCC (stages III to IVA) [26].